Connect with us

Technology

Purity, Potency of Pharmactive’s Aged Black Garlic Affirmed by Analytical Fingerprints

Published

on

Advanced mass spectrometry analysis confirms authenticity and bioactive levels of key compounds in Pharmactive’s Abg10+®

MADRID, Dec. 3, 2024 /PRNewswire/ — A new analytical study affirms the authenticity of Pharmactive Biotech Products, SLU’s Abg10+® proprietary aged black garlic (ABG) extract. The formulation is designed and science-backed to help promote cardiovascular health. In the current analysis, a comprehensive range of analytical “fingerprints” established the purity and natural status of the nutraceutical company’s best-selling composition, affirming the concentrated presence of its key bioactive compounds branded as Agedgarlides®. The primary compound included in Agedgarlides is S-allyl-L-cysteine (SAC), accompanied by other bioactives present, including S-1-propenyl-L-cysteine (S1PC) and S-allylmercaptocysteine (SAMC).

The new study addresses recent industry concerns over fraudulent and mislabeled natural supplements making their way to consumers. This analysis serves to reassure Pharmactive’s customers of the authenticity and potency of its products.

Commitment to authenticity

ABG products can become adulterated through various avenues. These include dilution to lower costs, use of fillers, or inclusion of undeclared synthetic compounds. Some low-quality products can contain pesticides and other contaminants; or, they can be subject to excessive heat, used to short cut the ageing process (which traditionally takes weeks). Gaps in regulations also open the door to mislabeling ABG products with claims of higher concentrations of bioactives than they have.

“Even with the implementation of regulatory measures, penalties, and enforcements to ensure honest labeling and safety, fraudulent products still manage to slip through the net,” denounces Carlos Rodríguez, Communications Manager for Pharmactive. “For that reason, we consistently evaluate our Abg10+ production from the raw material to the final product, applying in-process controls both in our factory and laboratory. We further conduct tests in clinical settings through third parties. All these safety and efficacy measures ensure that our customers are receiving is 100% authentic aged garlic components supported by science to deliver what is promised.”

Pharmactive produces its proprietary aged garlic extract using a traditional aging method on locally grown garlic bulbs. Under the 100%-natural process, the bulbs develop a characteristic natural beige hue and exhibit improved organoleptic properties that enhance their aroma and overall sensory appeal. This process also enriches the bulbs with potent antioxidants, including organosulfur compounds and polyphenols, as well as amino acids, among other beneficial compounds. The most prevalent of these is SAC, which can reach ten-fold higher concentration during true aging and is noted for its strong cardioprotective qualities.

Manufactured in Spain, the company applies a patented process known as ActiveNature™ Technology. This system is designed to optimize the extraction and preservation of 100% native SAC and other bioactive compounds from aged garlic through a unique aging technique  and eco-friendly water-based extraction.

100% aged garlic

“Our aged garlic extract is produced under controlled temperature, without burning, which prevents the formation of harmful substances such as acrylamide and furfurals. Our traditional approach to aging and advanced extraction methods enhances the bioactive compounds, resulting in a purer and more beneficial product,” adds Rodríguez.

The recent study, led by Ignacio Jiménez Amezcua, PhD and published August, 2024 in the scientific journal Foods, applied multiple analytical mass-spectral methodologies to generate “fingerprints” of Abg10+ compared to 24 other commercial aged garlic supplements. These fingerprints serve to verify the authenticity, purity, and consistency of the botanical material.

The application of analytical techniques such as liquid chromatography-mass spectrometry (LC-MS) and flow injection analysis–mass spectrometry (FIA-MS) revealed wide variability in SAC content of all 25 commercial aged garlic supplements. This included the bioactive diastereoisomer, S-1-propenyl-L-cysteine (S1PC), and a number of other organosulfur compounds typical to garlic. These are the key beneficial bioactives, noted for their positive influence on cardiovascular health, which are formed during the aging and extraction process. Only about half of the supplements analyzed contained the amount of SAC listed on their labels. Abg10+ demonstrated rich concentrations of 0.10% SAC and 0.03% S1PC, matching the amounts stated on its label.

Quality and quantity

Liquid Chromatography-Isotope Ratio Mass Spectrometry—an advanced analytical technique used for food authentication—determined the natural origin of the SAC content in Abg10+. The results revealed the presence of synthetic sources of SAC in other aged garlic supplement contenders. The carbon isotopic value of SAC in Abg10+ was found to be -28.0%, in line with the natural reference. Synthetic counterparts showed lower values of -22.3%, closely matching those observed for the synthetic SAC standard.

“Supplement adulteration is a more prevalent issue than many might assume,” laments Ignacio Jiménez. “It is quite common to find extracts or products that proclaim a specific bioactive but actually contain undeclared ingredients. A low price attached to an ABG supplement could indicate a lower-quality or even a completely fraudulent product.”

“In this market, standardization of active compounds makes all the difference,” adds Marina Díez Municio, Head of R&D and QC for Pharmactive. “There are many extracts on the market that only indicate the plant from which they are derived, the method of extraction and compliance with health requirements in line with the current relatively restrained regulations. But there is no proper characterization of the product, which is its fingerprint. We standardize our product using precise analytical tools that have demonstrated reproducible results,” stresses Díez Municio. Several studies have demonstrated Abg10+’s cardioprotective role, including its ability to favorably balance blood lipids, enhance vascular function, and improve antioxidant status. In two clinical trials, Abg10+ supplementation was associated with favorable reductions in both systolic and diastolic blood pressure.

“In a market where transparency and quality are essential, we have implemented the same standardization processes across our entire premium range, including Liboost®, Affroneye®, Olivactive® and others,” adds Díez Municio. “Through these measures, the company not only ensures the authenticity of its ingredients but also of their origin and quality. This has established each of our products as a trusted benchmark in the natural dietary supplements sector.”

About Pharmactive

Pharmactive Biotech Products, SLU, is a Madrid-based pioneering biotechnology company that develops, and manufactures differentiated natural ingredients supported by science, such as damiana extract, pure saffron extract, and aged garlic. The company’s mission is to make a daily positive and significant impact on people’s health and well-being through premium botanical ingredients backed by scientific studies and approved by ethics committees.

Company Contact:

Press Contact:

Pharmactive Biotech Products, S.L.U.

NutriPR

Carlos Rodriguez Iglesias

Communications Manager

Tel: +34 635785984

Email: carlos.rodriguez@pharmactive.eu             

Liat Simha

Tel: +972-9-9742893

E-mail: liat@nutripr.com

Twitter: @NutriPR_

Twitter: @Pharmactive_SP

Web: www.pharmactive.eu

Web: www.nutripr.com

Photo: https://mma.prnewswire.com/media/2571954/Pharmactive_Aged_BlackGarlic.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/purity-potency-of-pharmactives-aged-black-garlic-affirmed-by-analytical-fingerprints-302320808.html

SOURCE Pharmactive Biotech Products, S.L.U.

Continue Reading

Technology

Chemours Announces Dates for Third Quarter 2026 Earnings Release and Webcast Conference Call

Published

on

By

WILMINGTON, Del., Oct. 21, 2026 /PRNewswire/ — The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) today announced that the Company expects to issue its third quarter 2026 financial results after market on Monday, November 2, 2026.

The Company expects to hold its conference call to discuss its third quarter 2026 financial results at 8:00 a.m. Eastern Standard Time on Tuesday, November 3, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the “Events and Presentations” section of the Investor Relations section of Chemours’ website at investors.chemours.com.

Conference Call: Please visit investors.chemours.com for a link to the live webcast and to view the accompanying slides.

Replay: A webcast replay will be available at investors.chemours.com.

About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn. 

CONTACTS:

INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300 
investor@chemours.com 

NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-announces-dates-for-third-quarter-2026-earnings-release-and-webcast-conference-call-302915935.html

SOURCE The Chemours Company

Continue Reading

Technology

AGEDB Announces Preliminary Technical Evaluation of Graph Database and AI Data Platform Opportunities

Published

on

By

VANCOUVER, BC, Oct. 21, 2026 /CNW/ — AGEDB Technology Ltd. (TSXV: AGET) (“AGEDB” or the “Company”) announces that it is evaluating opportunities to re-engage in its historical graph database business area through preliminary architectural design and technical assessment of potential AI data platform applications, following its entry, on September 16, 2026, into a memorandum of understanding (the “MOU”) with a Korea-listed company exploring opportunities to enter the AI sector (the “Korean Company”).

The Company previously disclosed that it had discontinued its graph database management system operations during the year ended April 30, 2025 and was seeking new business opportunities. The Company is now assessing potential opportunities to leverage its existing Apache AGE-related technology and experience. These preliminary evaluations should not be interpreted as a resumption of full-scale development or commercial operations.

Under the MOU, AGEDB and the Korean Company contemplate evaluating an integrated package combining locally installed PostgreSQL and Apache AGE relationship-analysis database technology with an AI agent. The MOU also contemplates a separate “Personal AI Operating System” evaluation track, referred to as “AGE Brain,” for potential use in user-controlled computing environments. The proposed applications remain conceptual and subject to further technical and commercial assessment.

The contemplated preliminary work includes architectural design and technical evaluation of approaches to connecting relational data with graph-based relationships and supporting AI-assisted information retrieval and analysis. The parties may consider proof-of-concept testing and pilot activities, but no timeline or commitment to undertake such activities has been established under the MOU.

The MOU has a one-year term. Except for provisions expressly identified as binding, it is non-binding and does not require either party to complete development, launch or commercialize a product, make an investment, commit personnel, pay development fees, or enter into a definitive commercial agreement. Specific project scope, deliverables, schedules, responsibilities, costs and any commercialization terms remain subject to further discussions and, where applicable, separate written agreements. Each party will bear its own evaluation costs unless otherwise agreed in writing.

The Company’s evaluation remains preliminary. No product launch, commercial revenue or definitive commercialization arrangement has been agreed, and there can be no assurance that the parties will proceed with development, that the proposed platform will be completed or commercialized, or that the Company will obtain the resources required to advance the opportunity.

AGEDB may also explore potential collaborations with AI development companies in Korea and other markets, subject to available resources and further assessment.

AGEDB Technology Ltd.

On behalf of the board of directors,

“Jungsoo Kim”
CEO

About AGEDB Technology Ltd.

AGEDB Technology Ltd. is a technology company listed on the TSX Venture Exchange under the symbol “AGET.” The Company is focused on developing and pursuing opportunities in data intelligence, graph database technology and applied artificial intelligence.

Forward-Looking Information

This news release contains forward-looking information, including statements regarding the Company’s development activities, the proposed AI data platform, potential proof-of-concept and pilot activities, and possible future collaborations and commercialization. Forward-looking information is based on management’s current expectations and assumptions and is subject to risks and uncertainties that could cause actual results to differ materially. The memorandum of understanding is generally non-binding, and there can be no assurance that the parties will proceed with or complete any development, pilot, product launch or commercial arrangement, or that AGEDB will enter into additional collaborations. Readers are cautioned not to place undue reliance on forward-looking information. AGEDB undertakes no obligation to update such information except as required by applicable securities laws.

SOURCE AGEDB Technology Ltd.

Continue Reading

Technology

Bose Corporation Acquires Skullcandy, Expanding Its Consumer Audio Portfolio to Reach New Audiences

Published

on

By

Acquisition follows a successful partnership between the two companies and advances Bose’s evolution into a multi-brand products and technology company

FRAMINGHAM, Mass. and PARK CITY, Utah, Oct. 21, 2026 /PRNewswire/ — Bose Corporation, a global leader in audio innovation and research, announced today it has acquired Skullcandy, a lifestyle audio brand known for its bold products that bring together sound, style and performance. Bose and Skullcandy have each spent decades finding new ways to bring people closer to the music they love. Together, they’ll combine Bose’s audio expertise, technology and global reach with Skullcandy’s design, understanding of its consumers and authentic community connections to create new products and experiences and accelerate growth.

The acquisition follows a multi-year partnership that has already brought Sound by Bose technology to Skullcandy earbuds and headphones. The companies have seen firsthand how their strengths can come together to create products consumers love while staying true to what makes Skullcandy special, providing a foundation to accelerate further collaboration and innovation.

With a strong position at the intersection of audio, lifestyle and culture, Skullcandy will remain a separate brand within Bose’s Premium Consumer Audio business. Skullcandy’s deep roots in boardsports, including longstanding relationships with passionate supporters of the culture and its athletes, and authentic connections across music, gaming, fitness and other communities present new ways for Bose to meaningfully connect with consumers where it has less presence today.

“For more than 60 years, Bose has been committed to delivering incredible audio experiences however and wherever people choose to listen. As we work to reach even more people, we’re expanding how we do that, not only through Bose products, but through technology partnerships and a growing portfolio of brands,” said Lila Snyder, Chief Executive Officer of Bose Corporation. “As a privately held company, we have the freedom to make bold, long-term investments in opportunities we believe in, and Skullcandy is a great example of that. They have an established, thriving brand, and together we see tremendous opportunity to create new products and experiences and reach more consumers around the world.”

“We believe this is a win for Skullcandy and our fans,” said Brian Garofalow, Chief Executive Officer of Skullcandy. “Skullcandy was born on a chairlift in Park City, Utah, over 20 years ago, and we’ve always believed great music should be part of the experiences people love. Joining Bose gives us the opportunity to make those experiences even better by bringing more of their audio expertise and technology to our products, and it opens up even more ways to take Skullcandy further.”

Bose plans to invest in Skullcandy’s continued growth, providing greater access to technology, resources, global distribution and commercial relationships while giving the brand the freedom to continue evolving in ways that are authentic to its identity and consumers. Skullcandy will continue to be based in Park City, Utah.

Bose acquired Skullcandy from a fund managed by Mill Road Capital Management LLC, a Connecticut-based private investment firm. Jones Day acted as Bose’s legal counsel. Additional information, including financial and other terms of the transaction, will remain confidential.

About Bose Corporation
Bose Corporation is a global leader in audio innovation, driven by a singular belief: sound has the power to transform the way people connect with the world. For more than 60 years, Bose has combined pioneering research, engineering excellence, and a deep understanding of human perception to create products and technologies that deliver extraordinary experiences. Through its portfolio of iconic brands, including Bose, McIntosh, Sonus faber, and Skullcandy, the company offers premium and luxury audio solutions for the home, on the go, and in the car. Bose also collaborates with leading companies across industries, extending its audio expertise and technologies into new products, platforms, and applications beyond its own brands. 

Guided by a relentless spirit of innovation and a passion for what sound makes possible, Bose continues to advance the science and art of sound while expanding its impact on everyday life. From music and entertainment to communication, wellness, and emerging applications, Bose is creating new ways for people around the world to feel more connected, inspired, and engaged through the power of sound.

About Skullcandy
Founded in 2003 on a chairlift in Park City, Utah, Skullcandy is the original lifestyle audio brand. With deep roots in action sports culture, Skullcandy creates headphones, earbuds, and speakers that deliver powerful sound, bold style, and immersive experiences. Designed to move with you—from the mountains to the streets—Skullcandy gear is built to perform and made to stand out. Learn more at www.Skullcandy.com.

Contact

Joanne Berthaume
Joanne_berthaume@bose.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bose-corporation-acquires-skullcandy-expanding-its-consumer-audio-portfolio-to-reach-new-audiences-302915875.html

SOURCE Bose Corporation

Continue Reading

Trending